Tandem Diabetes initiated with a Buy at Redburn Atlantic

Redburn Atlantic initiated coverage of Tandem Diabetes with a Buy rating and $60 price target. Tandem has rapidly gained share in the durable pump market, thanks to its highly regarded t:slim X2 and focus on interoperability, the analyst tells investors in a research note. The firm sees a clear path towards profitability as Tandem matures, supported by a multi-year renewal tailwind and the transition to a multi-product portfolio.